These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22624634)

  • 21. The option value of delay in health technology assessment.
    Eckermann S; Willan AR
    Med Decis Making; 2008; 28(3):300-5. PubMed ID: 18480035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Describing practices of priority setting and resource allocation in publicly funded health care systems of high-income countries.
    Seixas BV; Regier DA; Bryan S; Mitton C
    BMC Health Serv Res; 2021 Jan; 21(1):90. PubMed ID: 33499854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustainability in Health care by Allocating Resources Effectively (SHARE) 10: operationalising disinvestment in a conceptual framework for resource allocation.
    Harris C; Green S; Elshaug AG
    BMC Health Serv Res; 2017 Sep; 17(1):632. PubMed ID: 28886740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Historical development of health technology assessment in Thailand.
    Teerawattananon Y; Tantivess S; Yothasamut J; Kingkaew P; Chaisiri K
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():241-52. PubMed ID: 19527543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using health technology assessment to identify gaps in evidence and inform study design for comparative effectiveness research.
    Tunis SR; Turkelson C
    J Clin Oncol; 2012 Dec; 30(34):4256-61. PubMed ID: 23071248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and implementation of health technology assessment in Argentina: two steps forward and one step back.
    Rubinstein A; Pichon-Riviere A; Augustovski F
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():260-9. PubMed ID: 19527545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A content analysis of Health Technology Assessment programs in Latin America.
    Arellano LE; Reza M; Blasco JA; Andradas E
    Int J Technol Assess Health Care; 2009 Oct; 25(4):570-6. PubMed ID: 19845988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Quality of health care, accreditation, and health technology assessment in Croatia: role of agency for quality and accreditation in health].
    Mittermayer R; Huić M; Mestrović J
    Acta Med Croatica; 2010 Dec; 64(5):425-34. PubMed ID: 21692267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hospital-based technology assessment programmes: two Canadian examples.
    Juzwishin D; Olmstead D; Menon D
    World Hosp Health Serv; 1996; 32(2):2-9. PubMed ID: 10165872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Informing disinvestment through cost-effectiveness modelling: is lack of data a surmountable barrier?
    Karnon J; Carlton J; Czoski-Murray C; Smith K
    Appl Health Econ Health Policy; 2009; 7(1):1-9. PubMed ID: 19558190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra.
    Claxton K; Sculpher M; McCabe C; Briggs A; Akehurst R; Buxton M; Brazier J; O'Hagan T
    Health Econ; 2005 Apr; 14(4):339-47. PubMed ID: 15736142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experiences with and impact of health technology assessment on the German Standing Committee of physicians and patients].
    Gibis B; Rheinberger P
    Z Arztl Fortbild Qualitatssich; 2002 Feb; 96(2):82-90. PubMed ID: 11921610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies.
    Ling DI; Lynd LD; Harrison M; Anis AH; Bansback N
    J Comp Eff Res; 2019 Jan; 8(1):7-19. PubMed ID: 30525982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health technology assessment in Poland and Scotland: comparison of process and decisions.
    Kolasa K; Wasiak R
    Int J Technol Assess Health Care; 2012 Jan; 28(1):70-6. PubMed ID: 22617739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expected value of information and decision making in HTA.
    Eckermann S; Willan AR
    Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of HTA research on policy decision-making.
    Youngkong S
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S119-26. PubMed ID: 24964709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health technology assessment in Australia: a role for clinical registries?
    Scott AM
    Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of health technology assessment in shaping the benefits package in The Netherlands.
    Stolk EA; de Bont A; van Halteren AR; Bijlmer RJ; Poley MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):85-94. PubMed ID: 19371181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies.
    Drummond M; Manca A; Sculpher M
    Int J Technol Assess Health Care; 2005; 21(2):165-71. PubMed ID: 15921055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective.
    Hao Y; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):447-54. PubMed ID: 23977973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.